Massachusetts AG presses Gilead on HCV pricing

In a letter to Gilead Sciences Inc. (NASDAQ:GILD) Chairman and CEO John Martin, Massachusetts Attorney General Maura Healey said her office is "considering whether Gilead's pricing strategy" for its HCV drugs Sovaldi sofosbuvir and Harvoni ledipasvir/sofosbuvir "may constitute an unfair trade practice in violation of Massachusetts law."

News of the letter, dated Jan. 22, came to light Wednesday. Gilead lost $2.58 to $89.63. ...